Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2017

View Archived Issues

ObsEva initiates phase III for nolasiban in ART

FDA accepts for filing Vraylar sNDA for maintenance treatment of schizophrenia

Cellceutix reports interim results from phase IIa trial of brilacidin in ulcerative colitis

FDA awards QIDP designation to Polypid's D-PLEX

Novel mouse model for evaluating the role of MMP7 in epithelial integrity and ciliogenesis in IPF

miRNAs as novel prognostic biomarkers in MGMT unmethylated glioblastomas

European orphan drug designation granted to CUR-1916 for Dravet syndrome

UMass Memorial Medical Center presents novel epigenetic biomarker data

Phase III NAVIGATE data for guselkumab presented at AAD meeting

Nicox resubmits NDA for AC-170

Significant efficacy seen with sarecycline in facial acne vulgaris

3-V Biosciences discloses novel mTOR and/or PI3K inhibitors

FDA accepts sBLA for Soliris in refractory generalized myasthenia gravis

SBIR grants supports CerSci's development of non-opioid drug candidates to treat neuropathic pain

FDA accepts sNDA for Auryxia

HNF-3A, a promising biomarker for the diagnosis of medullary thyroid carcinoma

Medshine Discovery patents vinyl compounds as FGFR and VEGFR inhibitors

TiGenix reports promising 2-year data from ADMIRE-CD study of Cx-601

Opthea discusses proposed phase IIb study of OPT-302 with FDA

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine develop IDO-1 inhibitors

Apricus completes sale to Ferring of Vitaros ex-U.S. rights

BerGenBio collaborates with Merck & Co. to study BGB-324 with pembrolizumab

Capnia completes merger with Essentialis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.